Department of Urology, Zhongshan Hospital, Fudan University, China.
Department of Urology, Changhai Hospital, Naval Medical University, China.
Dis Markers. 2021 Dec 24;2021:9573540. doi: 10.1155/2021/9573540. eCollection 2021.
Histone demethylase JMJD4 is a burgeoning tumor marker, which has been proven to be associated with colon cancer, but the role it plays in kidney cancer has not yet been investigated. In the present study, we evaluated whether JMJD4 can be a prognostic marker of patients with clear cell renal cell carcinoma (ccRCC) using data from public platform and experiments. Our results revealed that the expression of JMJD4 is higher in cancerous tissue than in normal tissues ( < 0.001). High expression of JMJD4 is associated with a poor overall survival (OS) of ccRCC as compared with low expression of JMJD4 ( = 0.015). JMJD4 showed significant relevance with M stage ( = 0.016), gender ( = 0.003), OS (0.018), disease-specific survival (DSS) (0.007), and percussion free interval (PFI) (0.041). Univariate and multivariate Cox analyses demonstrated that high JMJD4 expression had independent predictive value for OS in ccRCC patients (hazard ratio (HR) = 1.563, 95%confidence interval (CI) = 1.055-2.316, and = 0.026). Besides, experiments confirmed that high expression of JMJD4 can significantly promote the invasion ability ( < 0.001), cloning ability ( < 0.001), and proliferation ( < 0.001) of renal cell carcinoma. In summary, high JMJD4 expression may be a prognostic marker in patients with kidney cancer.
组蛋白去甲基化酶 JMJD4 是一种新兴的肿瘤标志物，已被证明与结肠癌相关，但它在肾癌中的作用尚未得到研究。在本研究中，我们使用公共平台和实验数据评估了 JMJD4 是否可以作为透明细胞肾细胞癌 (ccRCC) 患者的预后标志物。我们的结果表明，JMJD4 在癌组织中的表达高于正常组织 ( < 0.001)。与 JMJD4 低表达相比，JMJD4 高表达与 ccRCC 的总生存期 (OS) 较差相关 ( = 0.015)。JMJD4 与 M 期 ( = 0.016)、性别 ( = 0.003)、OS (0.018)、疾病特异性生存期 (DSS) (0.007) 和无进展间隔时间 (PFI) (0.041) 显著相关。单因素和多因素 Cox 分析表明，JMJD4 高表达对 ccRCC 患者的 OS 具有独立的预测价值 (风险比 (HR) = 1.563, 95%置信区间 (CI) = 1.055-2.316, = 0.026)。此外，实验证实 JMJD4 高表达可显著促进肾癌细胞的侵袭能力 ( < 0.001)、克隆能力 ( < 0.001) 和增殖能力 ( < 0.001)。总之，JMJD4 高表达可能是肾癌患者的预后标志物。
